• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头孢西丁在胸腔积液患者中的处置情况。

Disposition of cefoxitin in patients with pleural effusion.

作者信息

Barrueco M, Garcia M J, Otero M J, Dominguez-Gil A, de Letona J M

出版信息

Clin Ther. 1981;3(6):425-35.

PMID:7260988
Abstract

The pharmacokinetics of cefoxitin were studied in nine patients with pleural effusion of varied etiologies. All patients received a single intravenous bolus of 30 mg/kg. Cefoxitin levels were determined simultaneously in plasma and pleural fluid by means of a microbiologic plate diffusion method. The antibiotic follows a two-compartment open kinetic model. In the pleural fluid, maximum concentrations of cefoxitin of 19.72 +/- 9.72 microgram/ml were reached two hours after administration. The fraction of the antibiotic that reaches the pleural fluid represents 0.22% to 4.03% of the dose administered. The disappearance constant of the antibiotic from the pleural fluid is significantly smaller (Kd = 0.15 +/- 0.03 hours-1) than the elimination constant determined from the plasma levels (K13 = 2.27 +/- 0.90 hours-1). Cefoxitin was always found in antibacterial concentration in the pleural fluid for a considerable period of time.

摘要

在9例不同病因的胸腔积液患者中研究了头孢西丁的药代动力学。所有患者均接受30mg/kg的单次静脉推注。采用微生物平板扩散法同时测定血浆和胸腔积液中的头孢西丁水平。该抗生素遵循二室开放动力学模型。在胸腔积液中,给药后2小时头孢西丁的最高浓度达到19.72±9.72μg/ml。到达胸腔积液的抗生素分数占给药剂量的0.22%至4.03%。抗生素从胸腔积液中的消失常数(Kd = 0.15±0.03小时-1)明显小于从血浆水平测定的消除常数(K13 = 2.27±0.90小时-1)。在相当长的一段时间内,胸腔积液中总能检测到具有抗菌浓度的头孢西丁。

相似文献

1
Disposition of cefoxitin in patients with pleural effusion.头孢西丁在胸腔积液患者中的处置情况。
Clin Ther. 1981;3(6):425-35.
2
Pharmacokinetics of cefoxitin in patients with pleural effusion on a multiple dosage regimen.头孢西丁在多剂量方案下胸腔积液患者中的药代动力学。
Int J Clin Pharmacol Ther Toxicol. 1984 Jun;22(6):300-3.
3
Pleural fluid levels of cefoxitin in patients with renal impairment.肾功能不全患者胸腔积液中头孢西丁的水平。
Int J Clin Pharmacol Ther Toxicol. 1986 Sep;24(9):485-9.
4
Pharmacokinetics of cefoxitin administered by i.v. infusion to patients with a pleural effusion.静脉输注头孢西丁在胸腔积液患者中的药代动力学。
Eur J Clin Pharmacol. 1984;26(3):389-92. doi: 10.1007/BF00548772.
5
Influence of acute renal impairment in the penetration of cefoxitin into interstitial tissue fluid in rabbits.急性肾功能损害对头孢西丁在兔间质组织液中渗透的影响。
Clin Ther. 1981;3(6):413-24.
6
Amikacin pharmacokinetics in plasma and pleural fluid.
J Med Assoc Thai. 1989 Feb;72(2):90-6.
7
Disposition of cefoxitin in patients with ascites.头孢西丁在腹水患者中的处置情况。
Eur J Clin Pharmacol. 1981;20(5):371-4. doi: 10.1007/BF00615407.
8
Disposition of phosphomycin in patients with pleural effusion.磷霉素在胸腔积液患者中的处置情况。
Antimicrob Agents Chemother. 1984 Apr;25(4):458-62. doi: 10.1128/AAC.25.4.458.
9
Disposition of cefoxitin in the elderly.头孢西丁在老年人中的处置情况。
Int J Clin Pharmacol Ther Toxicol. 1980 Nov;18(11):503-9.
10
[Pharmacokinetics of a new antitumor antibiotic, neothramycin, after intrapleural administration].[新型抗肿瘤抗生素新制癌菌素胸腔内给药后的药代动力学]
Gan To Kagaku Ryoho. 1983 Jun;10(6):1504-10.

引用本文的文献

1
Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.重症患者的抗菌治疗:对导致药物处置改变和药代动力学变异性的病理生理状况的综述。
Clin Pharmacokinet. 2005;44(10):1009-34. doi: 10.2165/00003088-200544100-00002.
2
Disposition of cefoxitin in patients with ascites.头孢西丁在腹水患者中的处置情况。
Eur J Clin Pharmacol. 1981;20(5):371-4. doi: 10.1007/BF00615407.
3
Disposition of phosphomycin in patients with pleural effusion.磷霉素在胸腔积液患者中的处置情况。
Antimicrob Agents Chemother. 1984 Apr;25(4):458-62. doi: 10.1128/AAC.25.4.458.
4
The influence of uremia on the accessibility of phosphomycin into interstitial tissue fluid.尿毒症对磷霉素进入间质组织液的可及性的影响。
Eur J Clin Pharmacol. 1983;25(3):333-8. doi: 10.1007/BF01037944.